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Background and purpose: A pre-operative CT scan with contrast enhancement (CE) has recently been pro-
posed to improve tumorbed delineation in breast conserving therapy. However, it is not clear whether CE
is required for visualization of a known breast tumor. The main aims of this study were to compare the
sensitivity of a CE-CT scan with a native CT scan (i.e.without CE) and to identify characteristics predictive
for the requirement of CE.
Patients and methods: Both a CE-CT and a native CT were made in 58 breast cancer patients
(age 37–75 yr), prior to breast conserving surgery. Visibility of the tumor on CT was scored by three
observers (clearly visible/doubtful/not visible). Age, tumor size, palpable tumor yes/no, histology, and vis-
ibility on mammography were analyzed with respect to the visibility of the tumor on the native CT.
Results: The sensitivity for tumor detection was better for CE-CT (95%) than for native CT (83%)
(p < 0.001). Only mammographic visibility scores appeared to be signiﬁcantly correlated with the visibil-
ity of the tumor on the native CT (p = 0.013).
Conclusion: In most patients CE is not required to visualize a known breast tumor. Mammographic visi-
bility is a good parameter to decide on the use of CE.
 2011 Elsevier Ireland Ltd. Open access under the Elsevier OA license.
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Several studies have shown that application of a boost dose to
the tumorbed in patients treated with breast conserving therapy
(BCT) reduces the local recurrence rate with almost a factor 2 [1–
3] for all age groups. Nevertheless, the majority of local recurrences
still occurs in the tumorbed [1]. This may partly be explained by
the fact that delineation of the tumorbed for applying the boost
is associated with a large interobserver variation [4–8]. This uncer-
tainty in tumorbed delineation may not only be important for
delivering an adequate boost irradiation, but may also hamper
the feasibility of partial breast irradiation if delivered with post-
operative external beam radiotherapy. Consequently, there is a
need for improved tumorbed delineation.
Several approaches have been described to improve tumorbed
delineation, such as the use of clips, placed according to strict
guidelines [9,10], and the use of ultrasound and/or MRI [10,11].
Kirova et al. [12] suggested to make a pre-operative CT scan withrsity Medical Center, Depart-
– School for Oncology and
astricht, The Netherlands.
Boersma).
nder the Elsevier OA license.contrast enhancement (CE-CT) made in radiation treatment posi-
tion, and to register this CT-scan with the post-operative plan-
ning-CT scan, to improve localization of the tumorbed. Although
this image registration may be quite challenging due to surgery-
induced changes of the breast, we also wondered whether the
pre-operative CT was sufﬁciently sensitive to visualize the tumor.
Kirova et al. [12] reported that the tumor was visible in 20 out of
the 20 patients. Our group performed a pilot study using PET-CT
in 29 patients with advanced breast cancer or with recurrent
breast cancer [13]. Analysis of the CE-CT-data only, without taking
into account the PET data, showed that the breast tumors were vis-
ible on CT in 13 out of 17 patients (76%); including the knowledge
of the PET-data increased the detection rate by CT to 100%. In liter-
ature several other studies also reported a good sensitivity for CE-
CT [14–17]. Ternier et al. [14] found a 90% sensitivity and 90% spec-
iﬁcity for a CE-CT to detect a breast cancer recurrence, whereas
Uematsu et al. [15] even found a sensitivity of 100% in breast tu-
mors. Furthermore, Akashi-Tanaka et al. [16,17] claimed that CE-
CT was very good in detecting extensive intraductal components,
with a sensitivity of 82–88% and a speciﬁcity of 75–89%. These data
thus suggest that breast tumors may indeed be visible on a CE-CT.
It is however, not clear from the literature whether a known breast
tumor may also be visible on a native CT-scan, i.e.without CE. Since
a native CT is obviously more easy to acquire, without the risk of
272 Value of contrast-enhanced CT for breast tumorsadverse reactions, this is to be preferred if sufﬁciently sensitive.
The issue of sensitivity of the CT with or without CE is not only rel-
evant for improving tumorbed delineation, but may be even more
relevant when considering pre-operative radiotherapy.
The aim of the current study was, therefore, ﬁrst to compare the
sensitivity of a CE-CT scan with a native CT scan, in patients with a
known breast tumor, eligible for breast conserving therapy. The
second aim was to investigate whether we could identify factors
that can predict whether CE is required, such that CE only has to
be given in selected cases. Finally, an elementary comparison of tu-
mor size or volume was made between all imaging modalities and
pathology. The impact of a pre-operative CT on interobserver-
variation in tumorbed delineation will be reported in a separate
paper.
Patients and methods
Patient characteristics
Between September 2008 and October 2009, 60 female
cT1-2N0-1 breast cancer patients were included in a study aimed
at investigating the impact of a pre-operative CT scan on interob-
server variation in the tumorbed delineation [NCT00721058].
Fifty-eight of the 60 patients underwent both a pre-operative CT
scan with and without CE, and are subjects of investigation in
the current report. All patients were referred for pre-operative con-
sultation to the radiotherapy department (MAASTRO clinic), from
four different hospitals in the region. The patients were on average
59 years old (range 37–75 yrs). Eighteen out of the 58 tumors were
clearly palpable; 40 tumors were detected by the screening pro-
gram for detection of early breast cancer. In all patients regular
mammography and ultrasound of the tumor was available, with
tumor sizes on ultrasound varying from 0.4 to 2.6 cm. Thirteen pa-
tients had a conventional mammography, whereas 45 patients had
a digital mammography (Table 1).
All patients had a histologically proven breast cancer, a visible
mass on mammography or ultrasound and were eligible for breast
conserving therapy. All patients had a kreatinine clearance >60 mL/
min needed for intravenous contrast.
Patients were included in the study after giving written in-
formed consent. The study was approved by the Medical Ethics
Committee of the Maastricht University Medical Center, according
to the Dutch law and regulations.Acquisition of the CT data
Both a contrast-enhanced (CE)-CT and a native CT were made
with the patient in radiation treatment position. The patients were
scanned lying in supine position with the arms above the head in
an arm-support (Sinmed, Posirest-2), and the legs resting on a
Kneeﬁx (Sinmed). The palpable breast tissue (i.e. the Clinical Target
Volume (CTV)) was marked with a radio-opaque wire. In addition,
if a palpable tumor was present, this was marked as well. CT-Table 1
Patient characteristics (N = 58).
Average tumor size on ultrasound in cm (range) 1.29 (0.4–2.6)
Median age in yrs (range) 58.3 (37–75)
# of patients with digital mammography available (%) 45 (78%)
# of patients with a palpable tumor (%) 18 (31%)
# of patients with screen-detected tumor (%) 40 (70%)
# of patients with inﬁltrating ductal carcinoma (%) 50 (86%)
# of patients with inﬁltrating lobular carcinoma (%) 5 (9%)
# of patients with other histology than inﬁltrating lobular
or ductal carcinoma (%)
3 (5%)images were obtained at 3-mm slice thickness from the level of
the mandible down to the diaphragm (Siemens Somatom
Sensation).
First, a native CT-scan was made; immediately thereafter,
100 mL intravenous contrast (Xenetix 300) was injected, and an-
other CT was made 120 s after injection.Analysis of the CT-data
The visibility of the tumor on the CT was scored by three trained
radiation oncologists till consensus was reached for each individ-
ual patient. The observers had full knowledge of all available diag-
nostic information: physical examination, mammography and
ultrasound. For each patient, the native CT was analyzed prior to
analysis of the CE-CT, to prevent that knowledge of the CE-CT inﬂu-
enced the judgment of the native CT. The visibility was scored on a
3 point scale: clearly visible, doubtfully visible, not visible (Fig. 1).
In addition, the tumor volumes were delineated of those pa-
tients with a clearly visible lesion on the native CT, ﬁrst on the na-
tive CT, and thereafter on the CE-CT. All delineations were
performed by one observer (BH), who also had complete knowl-
edge of the diagnostic information.Analysis of the mammography
The visibility of the tumor on mammography was scored by a
panel of three radiation-oncologists. The visibility was classiﬁed
on a three-point scale: clearly visible, doubtfully visible and not
visible (Fig. 2).Statistical analysis
The ﬁrst aim of the current study was to compare the sensitivity
for tumor detection of the native CT with that of the CE-CT. Sensi-
tivity is usually deﬁned as the proportion (or percentage) of only
the patients with the condition under study that are correctly iden-
tiﬁed by the test. Since all the patients in this study have a breast
tumor, sensitivity refers to the proportion of all patients in this
study that are identiﬁed with either the native CT or the CE-CT.
All patients were included in a study aimed at investigating the
impact of a pre-operative CT scan on interobserver variation in the
tumorbed delineation [NCT00721058]. This number is sufﬁcient to
compare the sensitivity of the native CT and CE-CT with the follow-
ing assumptions. Assuming a 95% sensitivity of the CE-CT [14,15],
we could detect a 8.5% decrease in sensitivity of the native CT com-
pared to the CE-CT, with a power of 80% and an alpha of 0.05, with
the available data of the 58 included patients. To determine the
sensitivity for tumor detection, patients with either a visible or a
doubtfully visible tumor on CT were classiﬁed as visible.
Secondly, a univariate analysis (independent samples t-test for
continuous variables and a chi-square test for discrete variables)
was performed to test whether age, tumor size on ultrasound, pal-
pable tumor yes/no, histology, or visibility on mammography were
related to the visibility on the native CT. Visibility on CT was
dichotomized as yes or no. For this purpose, patients with a doubt-
ful visible tumor on CT were classiﬁed as visible. In addition, a
backward multivariate analysis was performed using logistic
regression analysis (SPSS package, version 17.0 for Windows
(SPSS INC 2009)) to control for confounding of predictor variables.
Finally, the tumor volumes as delineated on the CE-CT and on
the native CT were compared using a paired samples t-test, and
the Pearson correlation-coefﬁcient was calculated. Furthermore,
the largest diameter on the native CT was measured and compared
to the same measure on ultrasound and pathology, again using a
paired samples t-test and a Pearson correlation coefﬁcient.
Fig. 1. Example of a clearly visible (A), doubtfully visible (B) or invisible tumor (C) on the native CT (A1–C1), with the corresponding CE-CT (A2–C2).
Fig. 2. Example of a clearly visible (A), doubtfully visible (B) or invisible (C) tumor on the mammography.
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Sensitivity of the CE-CT the native CT
Of the 58 patients with a native CT, 41 (71%) tumors were
clearly visible, 10 (17%) tumors were not visible, and 7 (12%) were
doubtfully visible. For the CE-CT these ﬁgures were 54 (93%), 3 (5%)
and 1 (2%), respectively (Table 2).
To determine the sensitivity for tumor detection, patients with
a doubtfully visible tumor on CT were classiﬁed as visible. This re-
sulted in a sensitivity of the native CT of 83% versus a sensitivity for
the CE-CT of 95% (p < 0.001).
Predictive factors
The tumor was clearly visible on mammography in 34 of the pa-
tients (59%), doubtful in 17 patients (29%), and not visible in 7 pa-tients (12%). Univariate analysis showed that neither age, nor
tumor size, nor tumor palpable yes/no, nor histology showed a sig-
niﬁcant relation with the visibility of the tumor on the native CT.
The only factor that was signiﬁcantly related to the visibility of
the tumor on the native CT was the visibility of the tumor on mam-
mography (p = 0.013). The same was found when analyzing the
data with a backward multivariate analysis: only visibility of the
tumor on mammography appeared to be signiﬁcantly related to
the visibility of the tumor on the native CT (p < 0.01). This meant
that in 32 of the 34 patients (94%) with a clearly visible tumor
on mammography, the tumor was visible (N = 29) or doubtfully
visible (N = 3) on the native CT as well. Out of the two patients with
a tumor that was not visible on the native CT, in only one patient
the tumor was visible on the CE-CT. The positive predictive value
of the mammography for the visibility of the tumor on the native
CT was thus 85% (29/34) if only clearly visible tumors on CT were
Table 2
Visibility of the tumor on the CT with and without CE.
Visible on
native CT
Doubtfully visible
on native CT
Not visible
on native CT
Total
Visible on CE-CT 41 6 7 54
Doubtfully visible
on CE-CT
0 1 0 1
Not visible on CE-CT 0 0 3 3
Total 41 7 10 58
Table 3
Visibility of the tumor on the native CT (Table 3A) and on the CE-CT (Table 3B) in
relation to the visibility on mammography.
Number (%) Visible
on
native
CT
Doubtfully
visible on
native CT
Not
visible
on native
CT
Total
A
Visible on mammography 29 (50%) 3 (5%) 2 (3%) 34 (58%)
Doubtfully visible on
mammography
9 (16%) 2 (3%) 6 (10%) 17 (29%)
Not visible on
mammography
3 (5%) 2 (3%) 2 (3%) 7 (12%)
Total 41 (71%) 7 (12%) 10 (17%) 58 (100%)
B
Visible on mammography 33 (57%) 0 (0%) 1 (2%) 34 (59%)
Doubtfully visible on
mammography
15 (26%) 1 (2%) 1 (2%) 17 (29%)
Not visible on
mammography
6 (10%) 0 (0%) 1 (2%) 7 (12%)
Total 54 (93%) 1 (2%) 3 (5%) 58 (100%)
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Figure 3A
Figure 3B
Fig. 3. Tumor volume on the CE-CT versus the native CT, r2 = 0.87 (Figure 3A), and
maximum tumor diameter on the native CT, versus the maximum diameter on
ultrasound (open squares) and pathology (closed squares) (r2 = 0.53 and 0.18,
respectively), Figure 3B).
274 Value of contrast-enhanced CT for breast tumorscounted, and raised to (32/34) 94% if patients with a clearly and
doubtfully visible tumor on CT were taken together (Table 3).
Of the 24 patients with a doubtfully or invisible tumor on the
mammography, the tumor was nevertheless visible on the native
CT in 16 patients (66%). Out of these 16 patients, in 12 patients
the tumor was clearly visible and in four only doubtfully visible
(Table 3).Table 4
Number of required CE-CTs and of total required CTs, according to the followed
strategy to apply contrast-enhancement.
Native
CT only
CE-CT
only
Both native
and CE-CT
Total #
of CTs
Strategy 1: all patients CE-CT 0 58 0 58
Strategy 2: only CE-CT if not
visible on native CT
48 0 10 68
Strategy 3: CE-CT if not/poorly
visible on mammography
32 24 2 60Tumor volumes
The tumor volumes delineated on the CT with and without CE
were on average 1.6 cc (SD 1.7) and 1.7 cc (SD 2.0), respectively
(p > 0.05, paired samples t-test). The correlation between these
volumes was quite high, with a correlation coefﬁcient of 0.87
(Fig. 3A).
The average maximum tumor diameter on the native CT was
larger than on ultrasound and pathology (1.47 cm (SD 0.6) vs.
1.28 cm (SD 0.5) and 1.30 cm (SD 0.7), respectively. Only the differ-
ence between native CT and ultrasound showed a statistically sig-
niﬁcant difference of 0.31 cm (p < 0.001, paired samples t-test). In
addition, the maximum tumor diameter on the native CT only
poorly correlated with the maximum tumor diameter on ultra-
sound and pathology (Fig. 3B), with correlation coefﬁcients of
0.53 and 0.18 for the ultrasound and pathology, respectively.
Discussion
To our knowledge this is the ﬁrst study comparing the visibility
of a known breast tumor on a CT with and without contrast
enhancement (CE). We showed a clear superior sensitivity of CE-
CT, but even in the native CT, the sensitivity was reasonable (71–
83%). Consequently, CE is clearly not always required to visualize
the tumor. Minimizing the use of CE is obviously associated with
lower costs, more convenience for both the patient and logistics,
and without risk of adverse reactions. On the other hand, if CE isonly applied when the tumor is not visible on the native CT, a sec-
ond CT-scan with CE has promptly to be scheduled, causing trou-
blesome logistic consequences and inconvenience for the patient.
Below, we compared the consequences for three strategies for
selecting patients for contrast-enhancement (Table 4):
 Strategy 1: All patients receive CE. In our patient population, we
would have made 58 CTs, all with CE. Forty-one of these 58
(71%) patients would, however, not have needed CE, because
the tumor was (doubtfully) visible on the native CT as well.
 Strategy 2: Only patients with an invisible tumor on the native
CT receive CE. In that case, only 10 of the 58 patients (17%)
would need a CE-CT, but they would all have to come in for a
2nd time; in three of these 10 patients (30%) the tumor would
not be visible on the CE-contrast either. In total this would
result in 68 CTs, 58 native CTs and 10 CE-CTs.
 Strategy 3: Only patients with an invisible or doubtfully visible
tumor on mammography receive CE. In that case, 24 of the 58
patients (41%) would receive CE during their ﬁrst CT, but in
16 of these 24 (67%), CE would not have been required. Two
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but in only one of these the tumor would be visible on the CE-
CT. In total 60 CTs would be made, 34 native CTs and 26 CE-CTs.
Consequently, although the visibility on mammography had a
high positive predictive value, still 2/3 of the patients receiving
CE would not have needed it. Therefore, further studies are re-
quired to improve selection of patients requiring CE. For example,
we only used subjective interpretation of the mammography, in-
stead of objective imaging features. To counterbalance the inﬂu-
ence of subjectivity, we used three observers to score the
visibility on imaging; nevertheless, further studies could be fo-
cused onto trying to derive more objective imaging features e.g.
from MRI [18], ultrasound [19] or mammography that might be
predictive for visualization on CT. In addition, although we could
not demonstrate a difference between the visibility on conven-
tional mammography or digital mammography, one might specu-
late that the use of digital mammography would improve the
predictive value further, especially in pre- and peri-menopausal
patients younger than 50 years, with dense breasts [20].
The sensitivity of the CE-CT was quite similar to the sensitivity
mentioned in other studies [14–17]. However, we have to keep in
mind that in our study patients already had a proven breast
cancer, and the observers had all relevant information of other
imaging available, which was not the case in the other studies
[14–17].
Since the use of CE might inﬂuence the delineation of the tumor
itself, we also investigated whether a CE-CT would yield different
tumor volumes than the CT without CE. We found that if a pre-
operative CT is used for tumorbed delineation, the CE-CT and the
native CT without CE yielded similar results, provided that the tu-
mor can be visualized. However, it should be kept in mind that the
tumor diameter on CT shows a very poor correlation with the path-
ologic tumor diameter. In general, CT slightly overestimated the
diameter on pathology (regression line: y = 0.83x); this might
on one hand be explained by tumor shrinkage following ﬁxation,
but also by overestimation of the CT-size due to surrounding ede-
ma, or maybe even in situ carcinoma. In addition, inaccuracies in
the measurements may explain the poor correlation.
Two patients had a severe (>1 cm) underestimation of the tu-
mor on CT. One of these two patients had a lobular carcinoma
(the outlier on the graph with a size on pathology of 2 cm), which
is known to have a high risk of underestimation in imaging. The
other patient (the outlier on the graph, with a 4 cm size on pathol-
ogy), appeared to have a very fast growing tumor; in the waiting
time for surgery the tumor progressed that fast, that neo-adjuvant
chemotherapy was advised. If this patient was neglected, the over-
estimation of CT increased even further (regression line:
y = 0.78x). This patient should, therefore, be neglected in the cor-
relation of sizes between pathology and CT.
Current analyses are ongoing to investigate the value of a pre-
operative CT-scan with respect to inter-observervariation in
tumorbed delineation. The methods and results of that study will
be reported in another paper. If pre-operative imaging in treatment
position appears to have a positive effect on tumorbed delineation,
it may also be worthwhile to investigate the possibility to use an
MRI in treatment position, since MRI has cleary been shown to
have a much better correlation with pathology than CT [21].
Conclusion
We showed that a CE-CT has a higher sensitivity for visualizing
a known breast tumor than a CT without contrast. Nevertheless, by
using the visibility of the tumor on mammography as a predictivefactor for requiring CE, the use of CE can be prevented in almost
60% of the patients. Further studies are needed to improve the
selection of patients with a visible tumor on the native CT.
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